# US 2025/0145704 A1 · AUTOANTIBODIES AGAINST NaV1.5 CHANNEL AS BIOMARKERS FOR THE DIAGNOSIS OF BRUGADA SYNDROME AND RELATED THERAPEUTIC METHODS

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145704 A1
- Document ID: US20250145704A1
- Status: Published application
- Kind: A1
- Application number: 18/387,237
- Filed: 2023-11-06
- Published: 2025-05-08
- Earliest claimed: 2023-11-06
- Applicants: Cardiomix S.r.l.
- Inventors: Luigi ANASTASIA; Adriana TARANTINO; Andrea GHIROLDI; Giuseppe CICONTE; Carlo PAPPONE
- Web page: https://patentgrep.com/patent/US20250145704A1

## CPC

- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- G01N 33/6854: {Immunoglobulins}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to autoantibodies against NaV1.5 channel, their use as biomarker for the diagnosis of Brugada syndrome in human beings and relative methods of detection and therapeutic approaches to target this new discovered form of autoimmunity.

## Claims

### Claim 1

Autoantibodies directed against NaV 1.5 channel (SEQ ID NO:1) being biomarkers for the diagnosis of Brugada Syndrome in a human being.

### Claim 2 (depends on 1)

The autoantibodies for use according to claim 1, directed against a binding site of the extracellular loops of NaV 1.5 channel (SEQ ID NO:1).

### Claim 3 (depends on 2)

The autoantibodies for use according to claim 2, wherein said binding site is selected from the group consisting of:
i)
(SEQ ID NO: 2)
VFALIGLQLFMGNLRHKCVRNFTALNGTNGSVEADGLVWESLDLYLS
DPENYLLKNGTSDVLLCGNSSDAGTCPEGYRCLKAGENPDHGYTSFDSF
AWAFLALFRL
ii)
(SEQ ID NO: 3)
FGKNYSELRDSDSGLLPRWHMMDFFHAFLIIFRILCG
iii)
(SEQ ID NO: 4)
SIMGVNLFAGKFGRCINQTEGDLPLNYTIVNNKSQCESLNLTGELYW
TKVKVNFDNVGAGYLALLQ-1414
iv)
(SEQ ID NO: 5)
VILSIVGTVLSDIIQKYFFSPTLFRVIRLARIGRIL
v)
(SEQ ID NO: 6)
IYSIFGMANFAYVKWEAGIDDMFNFQTFANSMLCLFQI
vi)
(SEQ ID NO: 7)
AGWDGLLSPILNTGPPYCDPTLPNSNGSRGDCGSPAVGILFFTT.

### Claim 4 (depends on 1)

An in vitro method for detecting the presence or detecting the amount of at least one of the autoantibodies directed against the NaV 1.5 channel (SEQ ID NO:1) according to claim 1 comprising assaying a biological sample of a human being suspected of having Brugada Syndrome.

### Claim 5 (depends on 4)

The in vitro method according to claim 4, comprising:
a) contacting the biological sample with one or more antigens that specifically binds to the autoantibodies directed against NaV 1.5 channel (SEQ ID NO:1); and
b) detecting the binding of the antigen to the autoantibodies in the biological sample.

### Claim 6 (depends on 5)

The in vitro method according to claim 5, wherein said one or more antigens are labelled.

### Claim 7 (depends on 5)

The in vitro method according to claim 5, wherein said antigens are fragments of at least 10 amino acids from the binding sites of extracellular loops of NaV1.5 channel.

### Claim 8 (depends on 7)

The in vitro method according to claim 7 wherein said binding sites of extracellular loops of NaV1.5 channel are selected between SEQ ID NO:2-SEQ ID NO:7.

### Claim 9 (depends on 4)

The in vitro method according to claim 4, wherein the biological sample is selected from the group consisting of plasma, PBMCs, whole blood, serum and peripheral blood, and combinations thereof.

### Claim 10 (depends on 5)

The in vitro method according to claim 5, wherein the detection of the binding of the probe to the autoantibodies is performed by ELISA or Western blotting.

### Claim 11 (depends on 1)

A therapeutic method of treating Brugada Syndrome comprising administering an antagonist of the binding of the autoantibodies to the NaV 1.5 channel (SEQ ID NO:1) according to claim 1 in a patient.

### Claim 12 (depends on 1)

The therapeutic method of treating Brugada Syndrome comprising the step of administering an autoimmune therapeutic agent such as an antigen-specific tolerization of responses against NaV1.5 channel, specifically targeting to the autoantibodies directed to the NaV 1.5 channel (SEQ ID NO:1) according to claim 1 in a patient.

### Claim 13 (depends on 12)

The therapeutic method of treating Brugada Syndrome according to claim 12, wherein said autoimmune therapeutic agent comprises one or more antigenic fragments of the extracellular loops of the NaV 1.5 channel (SEQ ID NO:1).

### Claim 14 (depends on 12)

The therapeutic method of treating Brugada Syndrome according to claim 12, wherein said autoimmune therapeutic agent comprises sequences of at least about 10 amino acids from the extracellular loops of the NaV 1.5 channel, said extracellular loops being selected from the group consisting of SEQ ID NO:2-SEQ ID NO:7.

### Claim 15

A therapeutic method of treating Brugada Syndrome comprising the step of administering an immunomodulating or immunosuppressing drug non-specifically targeting the immune response against NaV1.5 by blocking antibody responses in a patient selected from the group consisting of Rituximab, Ocrelizumab, Ofatumumab, Inebilizumab Prednisone, Methylprednisolone, Dexamethasone, Colchicine and Hydroxychloroquine.

### Claim 16 (depends on 12)

The method of claim 12 wherein the antagonist or the autoimmune therapeutic agent is administered in combination with another therapy for Brugada Syndrome.

### Claim 17

A kit for detecting autoantibodies against NaV 1.5 channel in a biological sample, the kit comprising one or more antigens that specifically binds to the autoantibodies against NaV 1.5 channel (SEQ ID NO:1).

### Claim 18 (depends on 17)

The kit according to claim 17, wherein said antigens comprise one or more antigenic fragments of the extracellular loops of the NaV 1.5 channel, said antigenic fragments of the extracellular loops being selected from the group of sequences consisting of SEQ ID NO:2-SEQ ID NO:7.

### Claim 19 (depends on 17)

The kit according to claim 17, wherein said antigens are labelled or attached to a solid support.

### Claim 20 (depends on 1)

A method of diagnosing Brugada Syndrome comprising the step of detecting the presence of one or more autoantibodies according to claim 1, using one or more antigens that specifically bind to the autoantibodies against NaV 1.5 channel (SEQ ID NO: 1), wherein said biological sample is selected from the group consisting of plasma, PBMCs, whole blood, serum and peripheral blood, and combinations thereof.

### Claim 21 (depends on 1)

A method of monitoring the efficacy of a therapeutic treatment of Brugada Syndrome disease comprising the step of detecting the autoantibodies titer of autoantibodies according to claim 1 in a biological sample of a treated patient.

### Claim 22 (depends on 21)

The method of monitoring the efficacy of a therapeutic treatment of Brugada Syndrome disease according to claim 21, wherein said therapeutic treatment is pharmacological or interventional-surgical.

### Claim 23

An antigenic fragment of the extracellular loop of NaV 1.5 channel selected from the group consisting of the sequences SEQ ID NO:2-SEQ ID NO:7.
